Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer
Email
Facebook
Instagram
Twitter
YouTube
Search this website
International Alliance of ALS/MND Associations
Members' Login
Contact
Join the Alliance
Donate
What is ALS/MND
Find a Member Association
Support for PALS & CALS
Fundamental Rights of People with ALS/MND and Caregivers
Research
Voice Preservation
Open Science
Expanded Access
Understanding ALS/MND Research
Improving Regulatory Pathways
Right to Try
US FDA Orphan Drug Designation
Unproven (Off-Label) Treatments
Open Label Extension
Advocacy
Advocacy Toolkit
Emergency Preparedness Toolkit
Clinical Care
Genetic Counselling & Testing
Mental Health Support
Nursing and Symptom Management
Nutrition and Swallowing
Occupational Therapy and Activities of Daily Living
Physiotherapy and Mobility
Respiratory Care
Speech Therapy and Communication
Support for Family & Caregivers
Technology
Drugs in Development
AB Science – Masitinib
Amylyx – AMX0035
Biogen – Tofersen
BrainStorm Cell Therapeutics – NurOwn
Clene Nanomedicine – CNM-Au8
Collaborative Medicinal Development – CuATSM
Cytokinetics – Reldesemtiv
Kadimastem – AstroRx
Mitsubishi Tanabe Pharma America – Oral Edaravone
Orphazyme – Arimoclomol
T Regulatory Cell Therapies
Approved Drugs
Radicava/Edaravone
Neudexta
Riluzole/Tiglutik
Support for Health Professionals
Breaking the News in ALS/MND
Events/Programs
Calendar of Events/Programs
Alliance Webinars
Alliance Meeting
Allied Professionals Forum
ALS/MND Connect
Global Day
March of Faces
International Symposium on ALS/MND
About
Who We Are
Board of Directors
Committees/Advisory Councils
Scientific Advisory Council
PALS and CALS Advisory Council
Innovation and Technology Council
Governance Committee
Budget and Finance Committee
Staff
History
Archives
Newsletters
Meetings
Awards
Student Innovation Award Nomination
Forbes Norris Award Nomination
Humanitarian Award Nomination
Allied Health Professional Award Nomination
Members
Member Registration
Forgot Password
Riluzole/Tiglutik
Coming Soon!